Cigna Corporation has reinstated coverage of the Ambulatory Cardiac Telemetry (ACT) service and is retroactively effective as of June 15, 2014.

Lombard Medical Inc., a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA), today announced that its lead product, Aorfix, an endovascular stent graft to treat AAA, has received approval from the Japanese Ministry of Health, Labour and Welfare. Commercial sales will follow reimbursement approval. Aorfix will be exclusively distributed by Medico's Hirata Inc. Japan is the world’s second-largest standalone EVAR market.

The Cardiovascular Cell Therapy Research Network (CCTRN) has selected Cytori Therapeutics Inc. to supply adipose-derived regenerative cells (ADRC) for a clinical trial aimed at evaluating the safety and feasibility of treating patients with left ventricular assist devices (LVADs). The CCTRN is supported by grants from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient’s heart muscle 60 to 90 days after placement of an LVAD.

Healthcare organizations looking to implement low dose protocols for computed tomography (CT) exams on all scanners, regardless of disparate locations, can now benefit from SafeCT Enterprise from Medic Vision. The solution will be displayed at RSNA 2014.

Cardiothoracic and Vascular Surgeons became the first in Texas to implant the Solo Smart Aortic Pericardial Heart Valve. Faraz Kerendi, M.D. and Stephen J. Dewan M.D., performed the procedure at Heart Hospital of Austin.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now